ABCG2 and non-small cell lung carcinoma: In the present study of NSCLC patients receiving platinum-based treatment (n = 1004), we assessed the association of tagging and functional ABCG2 SNPs with objective response, survival and toxicities, and also tested the joint effects of ABCG2 and SLC31A1 polymorphisms on these clinical outcomes.